Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies (Q39987312)

16 September 2017

title

Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies (English)

1 reference

16 September 2017

4

Frits R Mooi

1 reference

16 September 2017

5

Hester E de Melker

1 reference

16 September 2017

Sabine C de Greeff

1

1 reference

16 September 2017

Anna K Lugnér

series ordinal

2

1 reference

16 September 2017

Danielle M van den Heuvel

series ordinal

3

1 reference

16 September 2017

language of work or name

English

0 references

publication date

31 January 2009

1 reference

16 September 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

16 September 2017

volume

27

1 reference

16 September 2017

issue

13

1 reference

16 September 2017

page(s)

1932-1937

1 reference

Resurgence of pertussis in Europe

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Pertussis resurgence in Canada largely caused by a cohort effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

The changing age and seasonal profile of pertussis in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Infant pertussis: who was the source?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

National study of infants hospitalized with pertussis in the acellular vaccine era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Transmission of Bordetella pertussis to young infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Potential strategies to reduce the burden of pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Economic burden of pertussis and the impact of immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Cost effectiveness of pertussis vaccination in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Pertussis in adolescents and adults: should we vaccinate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Hospitalization for pertussis: profiles and case costs by age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Societal costs and morbidity of pertussis in adolescents and adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Costs of illness due to Bordetella pertussis in families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Morbidity of pertussis in adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Symptoms and complications of pertussis in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Health-state valuations for pertussis: methods for valuing short-term health states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Economic impact of pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Adolescent and adult pertussis vaccination: computer simulations of five new strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Cost-effectiveness of adult pertussis vaccination in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

The case for maternal vaccination against pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.106

10.1016/J.VACCINE.2009.01.106

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference